Establishment Labs Holdings Inc. (ESTA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Establishment Labs Holdings Inc. (ESTA) trades at $72.67 with AI Score 32/100 (Grade D). Establishment Labs Holdings Inc. Market cap: $2.14B, Sector: Healthcare.
Price as of Aug 23, 2026 · Last analyzed: May 10, 2026ESTA stock analysis for 2026: Analysts have set a consensus price target of $85.50 for Establishment Labs Holdings Inc., suggesting 17.7% upside from the current price of $72.67. The AI MoonshotScore is 32/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ESTA: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Establishment Labs Holdings Inc. (ESTA) Healthcare & Pipeline Overview
Establishment Labs Holdings Inc. (ESTA) is a medical technology company specializing in aesthetic and reconstructive plastic surgery devices, primarily known for its Motiva Implants silicone gel-filled breast implants. Operating globally, ESTA distributes through exclusive partnerships and direct sales, holding a significant position in the international breast implant market.
What Is the Investment Thesis for ESTA?
Establishment Labs presents a compelling investment case driven by its innovative product portfolio and expanding global reach. The company's Motiva Implants have gained traction due to their advanced safety features and natural aesthetic outcomes, contributing to a gross margin of 70.1%. Key value drivers include continued expansion into new geographic markets, increased adoption of Motiva implants by plastic surgeons, and potential regulatory approvals in key markets like the United States. Upcoming catalysts include ongoing clinical trials and product development initiatives. Potential risks include competition from established players in the breast implant market and regulatory hurdles in different regions. With a market capitalization of $2.14B, Establishment Labs is positioned for growth in the aesthetic and reconstructive surgery market.
Based on FMP financials and quantitative analysis
ESTA Key Highlights
Market Cap of $2.14B reflects investor confidence in ESTA's growth potential.
- Gross Margin of 70.1% indicates strong pricing power and efficient operations.
- Profit Margin of -19.1% highlights ongoing investments in R&D and market expansion.
- Beta of 1.08 suggests ESTA's stock price is slightly more volatile than the market.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth.
Who Are ESTA's Competitors?
ESTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $106.49 | -1.21% | $9.25B | — |
| UFPT UFP Technologies, Inc. | $309.13 | +1.60% | $2.39B | 89 |
| INSP Inspire Medical Systems, Inc. | $62.36 | +1.78% | $1.80B | 97 |
| FDMDF 4DMedical Limited | $2.95 | +22.92% | $1.77B | 61 |
| CNMD CONMED Corporation | $51.07 | -0.60% | $1.53B | 76 |
| TMDX TransMedics Group, Inc. | $94.77 | +4.31% | $3.28B | 63 |
| IART Integra LifeSciences Holdings Corporation | $16.74 | +0.90% | $1.30B | 61 |
| IRMD IRadimed Corporation | $87.85 | +1.35% | $1.12B | 94 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ESTA's Key Strengths?
Innovative Motiva Implants with advanced safety features.
- Strong brand reputation and recognition.
- Exclusive distribution agreements in key markets.
- High gross margin of 70.1%.
What Are ESTA's Weaknesses?
Negative profit margin (-19.1%) indicates ongoing losses.
- Reliance on a single product category (breast implants).
- Limited presence in the United States market.
- High R&D expenses.
What Could Drive ESTA Stock Higher?
FDA approval decision for Motiva Implants in the United States.
- Expansion of distribution network in Asia-Pacific region.
- Clinical trials evaluating the safety and efficacy of Motiva Implants.
- Launch of new products for facial aesthetics and body contouring.
What Are the Key Risks for ESTA?
Competition from established players with greater market share.
- Regulatory delays or rejection of Motiva Implants in key markets.
- Product liability claims and litigation risks.
- Economic downturns affecting demand for cosmetic procedures.
- Fluctuations in currency exchange rates impacting international sales.
What Are the Growth Opportunities for ESTA?
- Expansion into the United States Market: Securing FDA approval for Motiva Implants in the U.S. represents a significant growth opportunity. The U.S. is the largest breast implant market globally, and entry could substantially increase revenue. The timeline for approval depends on ongoing clinical trials and regulatory review processes, but successful entry could unlock a market worth hundreds of millions of dollars annually.
- Geographic Expansion in Asia-Pacific: The Asia-Pacific region is experiencing rapid growth in aesthetic procedures. Expanding the distribution network and marketing efforts in countries like China, South Korea, and Japan can drive revenue growth. The market size in this region is substantial, with increasing disposable incomes and a growing interest in cosmetic enhancements. Establishment Labs can leverage its existing presence and brand recognition to capture a larger share of this market.
- Product Innovation and Pipeline Development: Investing in research and development to expand the product portfolio beyond breast implants represents another growth avenue. This includes developing new products for facial aesthetics, body contouring, and reconstructive surgery. A robust product pipeline can attract new customers and increase revenue streams. The timeline for new product launches depends on R&D progress and regulatory approvals, but successful innovation can drive long-term growth.
- Increased Adoption of Motiva Implants by Plastic Surgeons: Building relationships with plastic surgeons and increasing their adoption of Motiva Implants is crucial for growth. This can be achieved through educational programs, training workshops, and marketing campaigns that highlight the benefits of Motiva Implants. Increased surgeon adoption can lead to higher sales volumes and market share gains. The timeline for adoption depends on surgeon preferences and the effectiveness of marketing efforts.
- Leveraging the Puregraft Product Line: Expanding the sales and marketing efforts for the Puregraft line of products can contribute to revenue growth. Puregraft is used for autologous adipose tissue harvesting and redistribution, complementing breast augmentation and reconstruction procedures. Increasing awareness and adoption of Puregraft among plastic surgeons can drive sales and enhance Establishment Labs' position as a comprehensive provider of aesthetic solutions. The market for adipose tissue harvesting and redistribution is growing, presenting opportunities for Establishment Labs to capitalize on this trend.
What Are ESTA's Competitive Advantages?
- Innovative product design with advanced safety features in Motiva Implants.
- Strong brand reputation and recognition in the aesthetic surgery market.
- Proprietary technology and intellectual property related to breast implant design.
- Exclusive distribution agreements in key geographic markets.
What Does ESTA Do?
Establishment Labs Holdings Inc., incorporated in 2004 and headquartered in Alajuela, Costa Rica, is a medical technology company focused on designing, manufacturing, and marketing innovative medical devices for aesthetic and reconstructive plastic surgery. The company's flagship product is the Motiva Implants line of silicone gel-filled breast implants, known for their advanced design and safety features. These implants are available in various configurations, including the Motiva Ergonomix and Motiva Ergonomix2, which are gravity-sensitive round soft silicone-gel-filled breast implants designed to provide a more natural look and feel. In addition to breast implants, Establishment Labs offers the Motiva Flora Tissue Expander, a breast tissue expander used in reconstructive procedures. The company also distributes the Puregraft line of products, which are used for autologous adipose tissue harvesting and redistribution, complementing their breast augmentation and reconstruction offerings. Establishment Labs sells its products through a network of exclusive distributors and a direct sales force, reaching markets in Europe, Latin America, the Asia-Pacific region, and other international locations. The company continues to invest in research and development to expand its product portfolio and enhance its market position in the global aesthetic and reconstructive surgery market.
What Products and Services Does ESTA Offer?
- Manufactures silicone gel-filled breast implants under the Motiva Implants brand.
- Offers Motiva Ergonomix and Motiva Ergonomix2 gravity-sensitive breast implants.
- Provides Motiva Flora Tissue Expander for breast reconstruction.
- Distributes Puregraft products for autologous adipose tissue harvesting.
- Sells products through exclusive distributors and direct sales force.
- Focuses on aesthetic and reconstructive plastic surgery devices.
How Does ESTA Make Money?
- Designs, manufactures, and markets medical devices for aesthetic and reconstructive plastic surgery.
- Generates revenue through the sale of Motiva Implants and related products.
- Utilizes a distribution network of exclusive partners and a direct sales force to reach customers.
- Invests in research and development to innovate and expand its product portfolio.
What Industry Does ESTA Operate In?
Establishment Labs operates in the medical device industry, specifically within the aesthetic and reconstructive surgery market. This market is characterized by increasing demand for cosmetic procedures, driven by factors such as an aging population and growing awareness of aesthetic options. The competitive landscape includes established players with long-standing market presence. Establishment Labs differentiates itself through its innovative Motiva Implants, which emphasize safety and natural-looking results. The global breast implant market is projected to grow, presenting opportunities for Establishment Labs to expand its market share.
Who Are ESTA's Key Customers?
- Plastic surgeons who perform breast augmentation and reconstruction procedures.
- Hospitals and clinics that offer aesthetic and reconstructive surgery services.
- Patients seeking breast augmentation or reconstruction.
- Distributors who sell and market Establishment Labs' products in various regions.
Establishment Labs Holdings Inc. (ESTA) Valuation Context
Valued at $2.14B, ESTA is classified as a mid-cap stock. Relative to its peer group, ESTA's quantitative score of 32/100 is below the peer average of 81/100.
ESTA Revenue & Earnings Trend
In Q2 2026, ESTA generated $67.5M in top-line revenue, marking a sequential increase of 12.8%. The company recorded a net loss of $11.7M, with diluted EPS of $-0.39. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ESTA averaged $-0.33 in diluted EPS.
Company Profile
Establishment Labs Holdings Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Fillipo Peter Caldini. ESTA has traded publicly since 2018.
Key Financial Metrics
Return on assets is -12.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Establishment Labs Holdings Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.89 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Establishment Labs Holdings Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.4% above estimates on average.
Forward Outlook
Wall Street analysts project Establishment Labs Holdings Inc. revenue of about $270.1M for fiscal 2026, with EPS near $-1.20. The estimate reflects 6 contributing analysts.
ESTA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence in the company's future, suggesting that key stakeholders believe in its potential growth.
- Community sentiment has shifted positively as discussions around innovative product launches have gained traction, indicating increased consumer interest.
- Analysts note a strong pipeline of upcoming products that could enhance market position and drive revenue growth in the coming quarters.
- The company has been actively enhancing its brand presence, leading to improved recognition and trust among potential customers.
Bear Case
- Concerns about regulatory hurdles in the medical device sector have surfaced, creating uncertainty around product approvals and market entry timelines.
- Social sentiment reflects skepticism regarding the company's ability to scale operations effectively, with discussions highlighting potential operational challenges.
- Recent market developments have raised questions about competitive pressures, as new entrants are emerging in the same space, potentially impacting market share.
- Some community members express doubts about the sustainability of current growth trends, pointing to past volatility in the sector as a cautionary tale.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $68M | -$12M | -$0.39 |
| Q1 2026 | $60M | -$13M | -$0.45 |
| Q4 2025 | $65M | -$3M | -$0.09 |
| Q3 2025 | $54M | -$11M | -$0.38 |
Based on FMP financials and quantitative analysis
ESTA Latest News
ESTA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ESTA.
Price Targets
Consensus target: $85.50
ESTA MoonshotScore
What does this score mean?
The MoonshotScore rates ESTA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest Establishment Labs Holdings Inc. Analysis
Leadership: Fillipo Peter Caldini
Chief Executive Officer
Fillipo Peter Caldini is the Chief Executive Officer of Establishment Labs. His career spans various leadership roles in the medical device and healthcare industries. He brings experience in strategic planning, market development, and operational management. His expertise includes driving growth, innovation, and market expansion. He is responsible for overseeing the company's global operations and strategic direction, focusing on expanding market share and enhancing shareholder value.
Track Record: Under Fillipo Peter Caldini's leadership, Establishment Labs has focused on expanding its global presence and strengthening its product portfolio. Key achievements include driving revenue growth in international markets and advancing the regulatory approval process for Motiva Implants in the United States. Strategic decisions have focused on investing in research and development to enhance product innovation and improve patient outcomes. He manages 1034 employees.
Establishment Labs Holdings Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for ESTA?
ESTA holds an AI Score of 32/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Establishment Labs Holdings Inc. manufactures and markets medical devices for aesthetic and reconstructive plastic surgery, focusing on silicone gel-filled breast implants under the Motiva Implants …
What does Establishment Labs Holdings Inc. do?
Establishment Labs Holdings Inc. is a medical technology company that designs, manufactures, and markets medical devices for aesthetic and reconstructive plastic surgery. Its primary product is the Motiva Implants line of silicone gel-filled breast implants, known for their advanced design and safety features.
What do analysts say about ESTA stock?
Analyst coverage of Establishment Labs Holdings Inc. typically focuses on the company's growth prospects, driven by its innovative product portfolio and expanding global reach. Key valuation metrics include revenue growth, gross margin, and market capitalization. Analysts often consider the potential for FDA approval in the United States as a significant catalyst.
What are the main risks for ESTA?
The main risks for Establishment Labs Holdings Inc. include competition from established players in the breast implant market, regulatory hurdles and compliance requirements, product liability claims, and economic downturns affecting demand for cosmetic procedures. Regulatory risks include potential delays or rejection of Motiva Implants in key markets, such as the United States.
How does Establishment Labs Holdings Inc. navigate regulatory approval processes?
Establishment Labs navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. The company works closely with regulatory agencies, such as the FDA in the United States and the EMA in Europe, to ensure compliance with all applicable standards and requirements.
What is Establishment Labs Holdings Inc.'s strategy for competing with larger medical device companies?
Establishment Labs competes with larger medical device companies by focusing on product innovation, differentiation, and building strong relationships with plastic surgeons. The company's Motiva Implants are designed with advanced safety features and natural aesthetic outcomes, differentiating them from traditional breast implants. Establishment Labs invests in marketing and educational programs to increase awareness and adoption of its products among plastic surgeons.
What are the key factors to evaluate for ESTA?
Establishment Labs Holdings Inc. (ESTA) holds an AI score of 32/100 (low). Establishment Labs presents a compelling investment case driven by its innovative product portfolio and expanding global reach. Not financial advice.
How frequently does ESTA data refresh on this page?
ESTA's price was last updated on Aug 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ESTA's recent stock price performance?
Establishment Labs Holdings Inc. (ESTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Motiva Implants with advanced safety features. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are based on the most recent available data.
- Analyst opinions and ratings are not recommendations to buy or sell.